Abstract
Recently, intensive laboratory and preclinical studies have identified and validated therapeutic molecular targets in cancer, particularly the receptor tyrosine kinases, the intracellular pathways, and the genetic and epigenetic alterations, resulting in an unprecedented surge of novel, targeted therapies and therapeutic regimens. There are currently over 30 new agents being tested in the treatment of solid tumors as well as hematologic malignancies. Many of these are novel, targeted agents that have demonstrated significant efficacy and prolonged survival. Here, we discuss the current understanding of the mechanisms of action of novel molecular targeted cancer therapies being tested in the preclinical and clinical settings, including agents that act directly on the cell surface receptors, intracellular signaling pathways, and cell maintenance processes.
Keywords: Small molecule inhibitor, monoclonal antibody, antisense oligonucleotide, ell surface receptors, receptor tyrosine kinase, the intracellular pathway
Anti-Cancer Agents in Medicinal Chemistry
Title: Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Volume: 8 Issue: 5
Author(s): Hiroshi Yasui and Kohzoh Imai
Affiliation:
Keywords: Small molecule inhibitor, monoclonal antibody, antisense oligonucleotide, ell surface receptors, receptor tyrosine kinase, the intracellular pathway
Abstract: Recently, intensive laboratory and preclinical studies have identified and validated therapeutic molecular targets in cancer, particularly the receptor tyrosine kinases, the intracellular pathways, and the genetic and epigenetic alterations, resulting in an unprecedented surge of novel, targeted therapies and therapeutic regimens. There are currently over 30 new agents being tested in the treatment of solid tumors as well as hematologic malignancies. Many of these are novel, targeted agents that have demonstrated significant efficacy and prolonged survival. Here, we discuss the current understanding of the mechanisms of action of novel molecular targeted cancer therapies being tested in the preclinical and clinical settings, including agents that act directly on the cell surface receptors, intracellular signaling pathways, and cell maintenance processes.
Export Options
About this article
Cite this article as:
Yasui Hiroshi and Imai Kohzoh, Novel Molecular-Targeted Therapeutics for the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (5) . https://dx.doi.org/10.2174/187152008784533099
DOI https://dx.doi.org/10.2174/187152008784533099 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amrubicin: A Synthetic Anthracyclin Analogue in the Treatment of Extensive Stage Small Cell Lung Cancer
Recent Patents on Anti-Cancer Drug Discovery Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Genetics, Gene Expression, and Targeted Therapies in Chronic Lymphocytic Leukemia
Current Drug Targets Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Functional Role of miR-34 Family in Human Cancer
Current Drug Targets Thrombocytopenia in HIV Disease: Clinical Relevance, Physiopathology and Management
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Study of Common Bacterial and Fungal Pathogens in Children with Hematological Malignancies during Febrile Neutropenia: Single Center Egyptian Study
Infectious Disorders - Drug Targets Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Epigenetic Interventions Increase the Radiation Sensitivity of Cancer Cells
Current Pharmaceutical Design Non-Pharmacologic Strategies in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies
Current Cancer Drug Targets New Insights into Neuropeptides Regulation of the Immune System and Hemopoiesis: Effects on Hematologic Malignancies
Current Medicinal Chemistry Nelarabine- A New Purine Analog in the Treatment of Hematologic Malignancies
Reviews on Recent Clinical Trials K-Ras, Intestinal Homeostasis and Colon Cancer
Current Clinical Pharmacology Infrequent Infections in COPD
Current Respiratory Medicine Reviews DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets New Strategies in the Management of Children and Adolescents with Proliferative Lupus Nephritis
Current Rheumatology Reviews